Trihexyphenidyl: Difference between revisions

Trihexyphenidyl
	Black Box Warning
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

VisualWikitext

Revision as of 21:36, 23 December 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Black Box Warning

ConditionName:

See full prescribing information for complete Boxed Warning.

ConditionName:

Content

Overview

Trihexyphenidyl is a {{{drugClass}}} that is FDA approved for the {{{indicationType}}} of {{{indication}}}. There is a Black Box Warning for this drug as shown here. Common adverse reactions include nausea, xerostomia, dizziness, blurred vision, feeling nervous.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Parkinson's disease

Dosing Information

For treating PARKINSON'S DISEASE, an initial oral dose (tablet or elixir) of 1 milligram the first day followed by increases of 2 milligram increments at 3 to 5 day intervals to a total dose of 6 to 10 milligrams/day in 3 to 4 divided doses is recommended. Postencephalitic patients may require 12 to 15 milligrams/day.
It is recommended that trihexyphenidyl be taken in 3 divided doses at mealtime. If the total daily dose is greater than 10 milligrams/day it may be given in 4 divided doses (at mealtime and bedtime).
The recommended dose of trihexyphenidyl when used concomitantly with levodopa is 1 to 2 milligrams three times daily.
Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.

Parkinsonism due to drug

Dosing Information

For treating DRUG-INDUCED PARKINSONISM, five to 15 milligrams as a total daily dose is recommended to control extrapyramidal effects from phenothiazines, thioxanthenes and butyrophenones. It is recommended that therapy be initiated with a single 1-milligram dose. If the extrapyramidal manifestations are not controlled in a few hours, subsequent doses may be progressively increased until satisfactory control is achieved.
Satisfactory control may sometimes be more rapidly achieved by a temporary dose reduction of the tranquilizer when instituting trihexyphenidyl therapy and adjusting the dose of both drugs until the desired effect is obtained.
Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Trihexyphenidyl in adult patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trihexyphenidyl in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Trihexyphenidyl in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

Developed by:

Class of Recommendation:

Strength of Evidence:

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Trihexyphenidyl in pediatric patients.

Non–Guideline-Supported Use

Condition1

Dosing Information

Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Trihexyphenidyl in pediatric patients.

Contraindications

Condition1

Warnings

ConditionName:

See full prescribing information for complete Boxed Warning.

ConditionName:

Content

Description

Precautions

Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Trihexyphenidyl in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Trihexyphenidyl in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

Drug

Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

Pregnancy Category

Pregnancy Category (AUS):

Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Trihexyphenidyl in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Trihexyphenidyl during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Trihexyphenidyl with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Trihexyphenidyl with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Trihexyphenidyl with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Trihexyphenidyl with respect to specific gender populations.

Race

There is no FDA guidance on the use of Trihexyphenidyl with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Trihexyphenidyl in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Trihexyphenidyl in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Trihexyphenidyl in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Trihexyphenidyl in patients who are immunocompromised.

Administration and Monitoring

Administration

Oral

Intravenous

Monitoring

There is limited information regarding Monitoring of Trihexyphenidyl in the drug label.

Description

IV Compatibility

There is limited information regarding IV Compatibility of Trihexyphenidyl in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

Description

Management

Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Trihexyphenidyl in the drug label.

Pharmacology

There is limited information regarding Trihexyphenidyl Pharmacology in the drug label.

Mechanism of Action

Structure

File:Trihexyphenidyl01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Trihexyphenidyl in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Trihexyphenidyl in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Trihexyphenidyl in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Trihexyphenidyl in the drug label.

How Supplied

Storage

There is limited information regarding Trihexyphenidyl Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Trihexyphenidyl |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Trihexyphenidyl |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Trihexyphenidyl in the drug label.

Precautions with Alcohol

Alcohol-Trihexyphenidyl interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Artane, Trihexane, Tritane.

Look-Alike Drug Names

A® — B®^[1]

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

↑ "http://www.ismp.org". External link in |title= (help)

{{#subobject:

 |Page Name=Trihexyphenidyl
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Trihexyphenidyl
 |Label Name=Trihexyphenidyl11.png

}}

{{#subobject:

 |Label Page=Trihexyphenidyl
 |Label Name=Trihexyphenidyl11.png

}}

[www.ismp.org-1] "http://www.ismp.org". External link in |title= (help)

[1]

@@ Line 1: / Line 1: @@
 {{DrugProjectFormSinglePage
-|authorTag=<!--Overview-->
+|authorTag={{DB}}
 |aOrAn=a
-|drugClass=
-|indicationType=
-|indication=
 |hasBlackBoxWarning=Yes
-|adverseReactions=<!--Black Box Warning-->
+|adverseReactions=[[nausea]], [[xerostomia]], [[dizziness]], [[blurred vision]], feeling nervous
 |blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
@@ Line 15: / Line 12: @@
 <!--FDA-Labeled Indications and Dosage (Adult)-->
-|fdaLIADAdult======Condition1=====
+|fdaLIADAdult======Parkinson's disease=====
 * Dosing Information
-:* Dosage
+:* For treating PARKINSON'S DISEASE, an initial oral dose (tablet or elixir) of 1 milligram the first day followed by increases of 2 milligram increments at 3 to 5 day intervals to a total dose of 6 to 10 milligrams/day in 3 to 4 divided doses is recommended. Postencephalitic patients may require 12 to 15 milligrams/day.
+:* It is recommended that trihexyphenidyl be taken in 3 divided doses at mealtime. If the total daily dose is greater than 10 milligrams/day it may be given in 4 divided doses (at mealtime and bedtime).
+:* The recommended dose of trihexyphenidyl when used concomitantly with levodopa is 1 to 2 milligrams three times daily.
+:* Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
-=====Condition2=====
+=====Parkinsonism due to drug=====
 * Dosing Information
-:* Dosage
+:* For treating DRUG-INDUCED PARKINSONISM, five to 15 milligrams as a total daily dose is recommended to control extrapyramidal effects from phenothiazines, thioxanthenes and butyrophenones. It is recommended that therapy be initiated with a single 1-milligram dose. If the extrapyramidal manifestations are not controlled in a few hours, subsequent doses may be progressively increased until satisfactory control is achieved.
+:* Satisfactory control may sometimes be more rapidly achieved by a temporary dose reduction of the tranquilizer when instituting trihexyphenidyl therapy and adjusting the dose of both drugs until the desired effect is obtained.
-=====Condition3=====
+:* Sustained release capsules should not be used for initial therapy due to the high dosage per capsule. After patients are stabilized on conventional therapy they may be switched to the sustained release form on a milligram for milligram basis as a single dose or 2 divided doses 12 hours apart.
-* Dosing Information
-:* Dosage
-=====Condition4=====
-* Dosing Information
-:* Dosage
 <!--Off-Label Use and Dosage (Adult)-->
@@ Line 251: / Line 241: @@
 <!--Use in Specific Populations-->
-|FDAPregCat=
 |useInPregnancyFDA=* '''Pregnancy Category'''
 |useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
@@ Line 318: / Line 307: @@
 <!--How Supplied-->
 |howSupplied=*
-|storage=
+|packLabel=<!--Patient Counseling Information-->
-|packLabel=
-<!--Patient Counseling Information-->
 |fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
@@ Line 327: / Line 314: @@
 <!--Brand Names-->
-|brandNames=* ®<ref>{{Cite web | title =  | url =  }}</ref>
+|brandNames=Artane,
+Trihexane,
+Tritane.
 <!--Look-Alike Drug Names-->